As CEO Dr. Hansel is responsible for business development at oncgnostics. He has long-lasting experience in project management obtained while working at several universities in Germany and abroad as well as operative experience in industrial product development, sales and marketing.
The spin-off of oncgnostics is based on his research as well as works of a project group at the university hospital, which he has led.
For the past 18 years, Ali Ardakani has been pivotal in start-up and development of several biotech companies, drugs and medical devices, for which he has raised over $100 M USD in private and grant financing.
Most recently, he co-founded virtual biotech Niiki Pharma Inc in NYC, where he acquired two first-in-class oncology drugs from Europe and took them through US IND, UK CTA and Phase 1 and 2 clinical trials within 3 years.
Austin is Vice President, Emerging Technologies at Precision for Medicine, where he specializes in the design and execution of to-market clinical and regulatory strategies for innovative, first-in-class diagnostics, digital health and medical device technologies.
Professional interests include personalized medicine, advanced diagnostics, mobile and digital health, bioinformatics, deep learning, advanced study designs, preventative and integrated care, user experience/product design, and branding and communicating innovation.
Birgitte Booij, Ph.D., is Vice President Product and Business development at SpinChip Diagnostics, a startup company developing a new state of the art platform for in vitro diagnostics aimed at the Point of Care market.
Booij holds a PhD in biotechnology from the University of Cambridge and a masters’ degree in chemistry from the University of Groningen.
Mr. Christopher Ung led the global development and commercialization efforts of HercepTest™ and pharmDx EGFR companion diagnostic assays. He continues to lead and implement global biomarker strategies for drug development and companion diagnostic projects. He has set up CAP, CLIA laboratories in the US, Scotland, China, and Singapore, all of which are connected via a digital pathology WSI scanning and analysis platform.
Mr. Faulkner brings approximately 20 years of experience in the healthcare industry focusing on value demonstration, market access and commercialization of emerging health technologies. Mr. Faulkner is a recognized global thought leader in personalized medicine/diagnostic, regenerative medicine, biopharmaceutical, and medical technology market access, with extensive publication and over 80 global panel sessions on these topics.
Gary Gustavsen joined Health Advances in 2005 and leads its PrecisionMedicine Practice. A noted writer and workshop leader in the field of companion diagnostics and personalized medicine, his work focuses on commercialization strategy, indication prioritization, pricing and reimbursement strategy, system economics, and business development opportunities for both diagnostic and therapeutic clients.
Harry Glorikian is an influential global business expert with more than three decades of experience building successful ventures in North America, Europe, Asia and the rest of the world. Harry is well known for achievements in life sciences, healthcare, healthcare IT and the convergence of these areas. He is a sought-after speaker, frequently quoted in the media, and regularly asked to assess, influence, and be part of innovative concepts and trends. He holds four US patents in telecommunications, and has others pending.
Henrik Winther has been at the forefront of companion diagnostics for over 10 years. He brings solid experiences within R&D, business development, regulatory, manufacturing and commercialization of IVD products.
From 2006, Henrik was R&D Director at Dako A/S and spearheaded the design responsibility of their most successful product, the HercepTest CDx assay, and later was Head of Dako Business Development and involved in the acquisition of Dako by Agilent Technologies.
Jakob Gjørret is Managing Director, CEO for Unilabs Denmark in Copenhagen and is also leading Unilabs Group initiative for Serving Pharma, with efforts to combine and align capabilities for bioanalysis in drug development and commercializing drug associated diagnostic services. Before joining Unilabs in 2017 he was Director of Alliance Management within Agilent’s Companion Diagnostics division.
Mr. Jones joined SkylineDx as the Executive Vice President, Commercial Operations in August 2015. He brings more than twenty-five years of experience to SkylineDx as a proven commercial leader in the global in-vitro diagnostics industry.
Prior to that, Jeff worked for several Fortune 500 companies to include: Abbott Diagnostics, Bayer Healthcare, and Quest Diagnostics where he held both regional and global positions of increasing responsibility. Jeff received his undergraduate degree from UCLA.
Dr. Jürgen Doppke, received his PhD from the Ruhr University in Bochum in cooperation with Boehringer Ingelheim. Subsequently he gained 15 Years Experience in various Roles as Sales- and Product Specialist, Field Application Scientist and Product Line Leader for Lab Automation, Research Instrumentation and High Content Screening Products for Companies like Beckman Coulter, Molecular Devices and Perkin Elmer.
Dr. Martina Kaufmann, Managing Director at Martina Kaufmann Strategic Consulting (www.mk-stracon.com) has 15+ years industry experience in the field of personalized medicine – from biomarker validation, companion diagnostics development to implementation of such products in the market.
Dr. Morteza Minaee has more than 25 years of experience in the FDA-regulated medical devices and global diagnostic industry leading regulatory, quality-systems, and clinical-affairs organizations.
With over 25 years of drug R&D experience and years of experience in translational and diagnostics, Nick is now the board chairman and CEO for QIAGEN (Suzhou) Translational Medicine Co. Ltd. that provides an integrated technology platform for biomarker, companion diagnostics development and clinical testing for precision medicine.
Paul has worked for pharma/biotech and services companies since completing his post-doctoral studies in the late 1990s.
For the last 5 years he has worked on Personalised Healthcare and CDx partnerships and projects which has led to an in depth understanding of the relationships between the contract provider and acceptor, enabling him to engage and empathise whether for transactional business or strategic partnerships.
Currently Vice President, Discovery Research at hVIVO (formerly RetroScreen Virology Ltd) with responsibility for strategic direction and leadership of scientific activities aimed at identifying and developing drug targets and biomarkers for respiratory disease.
Robert Hawkins is Cancer Research UK Professor at the University of Manchester and Christie Hospital. In addition to clinical training he was an MRC Research Fellow with Dr Greg Winter and Dr Cesar Milstein at the MRC laboratory of Molecular Biology in Cambridge.
Rohit’s interests lie at the intersection of healthcare and technology. As the SVP, Product Strategy & Partner Integration at Treato, he manages Treato’s Product & Innovation portfolio through bridging technological solutions and market need. Additionally, Rohit is the Product Advisor to NeuroLex Dx, a startup developing voice-based diagnostics for mental health disorders.
Stefan Müllner, a chemist by training, did his Ph.D. thesis in protein biochemistry and postdoc in molecular biology. During his long time as CEO of Protagen AG, he grew the company into the global technology leader in blood based patient stratification to enable novel autoimmune therapy.
Susanne Munksted holds a Master of Science in Pharmaceutical Sciences from The Royal Danish University of Pharmacy, followed by an Executive CBA (Certificate in Business Administration) and a number of Diplomas in People Management and Sales and Marketing. She worked +10 years in various International Commercial roles in the pharmaceutical industry before joining Agilent (before Dako) in 2009 and is now Global Commercial Director for Companion Diagnostics.